Yahoo Finance Today's Research Reports on Emblem, OrganiGram, Oncolytics Biotech and Aptose Biosciences
NEW YORK, NY / ACCESSWIRE / July 11, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI Initiates Coverage on:
Emblem Corp.
https://rdinvesting.com/news/?ticker=EMC.V
OrganiGram Holdings Inc.
https://rdinvesting.com/news/?ticker=OGI.V
Oncolytics Biotech Inc.
https://rdinvesting.com/news/?ticker=ONC.TO
Aptose Biosciences Inc.
https://rdinvesting.com/news/?ticker=APS.TO
Emblem's stock had no change Tuesday, to close the day at $1.28. The stock recorded a trading volume of 124,012 shares, which was below its three months average volume of 380,350 shares. In the last year, Emblem's shares have traded in a range of 1.15 - 26.32. The stock is currently trading 95.14% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $1.43 is below its 200-day moving average of $1.60. Shares of Emblem have fallen approximately 43.86 percent year-to-date.
Access RDI's Emblem Corp. Research Report at:
https://rdinvesting.com/news/?ticker=EMC.V
On Tuesday, shares of OrganiGram recorded a trading volume of 567,459 shares, which was below the three months average volume of 766,884 shares. The stock ended the day 0.59% lower at 5.04. The share price has gained 147.06% from its 52 week low with a 52 week trading range of 2.04 - 5.93. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $5.25 is greater than its 200-day moving average of $4.50. Shares of OrganiGram have gained approximately 22.93 percent year-to-date.
Access RDI's OrganiGram Holdings Inc. Research Report at:
https://rdinvesting.com/news/?ticker=OGI.V
Oncolytics Biotech's stock moved 4.74% lower Tuesday, to close the day at $7.44. The stock recorded a trading volume of 12,295 shares, which was below its three months average volume of 158,931 shares. In the last year, Oncolytics Biotech's shares have traded in a range of 4.48 - 10.67. The share price has gained 66.07% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $8.48 is greater than its 200-day moving average of $7.41. Shares of Oncolytics Biotech have gained approximately 10.03 percent year-to-date.
Access RDI's Oncolytics Biotech Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ONC.TO
On Tuesday, shares of Aptose Biosciences recorded a trading volume of 31,579 shares, which was below the three months average volume of 38,858 shares. The stock ended the day 2.60% lower at 4.49. The share price has gained 173.78% from its 52 week low with a 52 week trading range of 1.64 - 5.97. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $5.02 is greater than its 200-day moving average of $4.16. Shares of Aptose Biosciences have gained approximately 61.51 percent year-to-date.
Access RDI's Aptose Biosciences Inc. Research Report at:
https://rdinvesting.com/news/?ticker=APS.TO
Our Actionable Research on Emblem Corp. (TSX-V: EMC.V) and OrganiGram Holdings Inc. (TSX-V: OGI.V) and Oncolytics Biotech Inc. (TSX: ONC.TO) and Aptose Biosciences Inc. (TSX: APS.TO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
